ArticleCancer biology & medicine2024

Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer.

Qin Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.